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ABSTRAK 
Satu kajian telah dibuat keatas 84 pesakit kanak-kanak dan dewasa yang mengalami 
penyakit leukemia akut antara Januari 2003 sehingga Januari 2005. Kes-kes tersebut telah 
diklasifikasikan secara morfologi dan immunofenotip. 93 pesakit telah didiagnosakan 
mengalami leukemia akut. Walaubagaimanapun hanya 84 rekod yang lengkap dan dapat 
dianalisa secara keseluruhan. 
1 
Berdasarkan klasifikasi F AB, 43 pesakit diklasifikasikan sebagai Myeloid Leukemia 
Akut (AML) dan 41 pesakit adalah Limfoblastik Leukemia Akut (ALL). Jenis-jenis leukemia 
yang diklasifikasikan secara immunofenotip adalah AML sebanyak 51%, B-ALL (31% ), T-
ALL (14%) dan Acute Biphenotypic Leukemia (4%). 
Kajian ini diharapkan dapat memberi kesan informasi kepada bidang kesihatan 
terutama dalam pengdiagnosan penyakit akut leukemia dan seterusnya memberi manfaat 
kepada semua yang terlibat dalam memberi rawatan terbaik kepada pesakit akut leukemia 
khususnya. 
ABSTRACT 
A review has been made of the 84 paediatric and adult cases of acute leukemia 
between January 2003 until January 2005. These cases were classified morphologically 
(using FAB classification) and immunophenotypically. A total of93 paediatric and adult 
cases were diagnosed, however only 84 records of patients were retrievable from 
Haematology Lab record books. 
By F AB classification, 43 cases were classified as Acute Myeloid Leukemia (AML) 
and 41 cases as Acute Lymphoblastic Leukemia. Acute Leukemia was 
immunophenotypically classified as AML with 51%, B-ALL (31%), T-ALL (14%), 
Acute Biphenotypic Leukemia ( 4% ). 
Contribution of Flow Cytometry analysis to patient is dynamic and evolving with 
_clinical relevance of biologic parameters and also for the prognostic information. This study 
was hope to give some benefit in the information which could be used in health area 




1.1 Acute Leukemia 
Acute leukemia is usually aggressive diseases in which the malignant transfonnation 
causes accumulation of early bone marrow haemopoietic progenitors, called blast cells. It is a 
heterogeneous group of malignancy with varying clinical, morphologic, immunologic and 
molecular characteristics. Many distinct types are known to carry predictable prognoses and 
warrant specific therapy. Distinction between lymphoid and myeloid leukemia, most often 
made by flow cytometry, is crucially important. Several advances in flow cytometry, 
including availability of new monoclonal antibodies, improved gating strategies and 
multi parameter analytic techniques have all dramatically improved the utility of flow 
cytometry in diagnosis and classification of acute leukemia. 
Acute leukemia is defined as the presence of over 300.4, of blast cells in the bone 
marrow at clinical presentation. It is further subdivided into acute myeloid leukemia (AML) 
and acute lymphoblastic leukemia (ALL) on the basis whether the blasts are shown to be 
myeloblasts or lymphoblast. In most cases, the clinical features and morphology on routine 
staining distinguish ALL from AML. Specialized tests are needed to confirm the diagnosis of 
ALL or AML and to subdivide the cases into their different subtypes. These include 
cytochemical stains, immunophenotyping by flow cytometry, chromosomal studies, and 
molecular studies. 
The first accurate description of a case of leukemia was given in 1827 by Velpeau. 
His patient, a florist and lemonade seller age 63 years had abandoned himself and fell ill in 
1825 with a pronounced swelling of the abdomen, fever and weakness. He died soon after 
admission to hospital and at autopsy, was found to have a massive enlargement of the liver 
and spleen. The blood was thick and described as resembling the colour of the yeast of red 
Wine. 
1.2 Epidemiology of acute leukemia 
1.2.1 Age and sex 
Acute leukemia occurs at all ages, but its frequency rises steeply with increasing age 
beyond 50 years. Acute myeloblastic leukemia (AML) accounts for the great majority of 
adult cases while acute lymphoblastic leukemia (ALL) predominates among children. 
Generally, acute leukemia is more common in males than females. 
1.2.2 Ethnic and social class differences 
Acute leukemia in all ages is more common in whites than in blacks. These 
differences are thought to reflect differences in environmental exposure. Acute leukemia is 
also observed more commonly in higher than lower socio-economic groups. 
1.2.3 Exposure to radiation 
The capacity of ionizing radiation to cause leukemia has long been recognized. 
FoiJowing the 1945 atom bomb explosion in Hiroshima and Nagasaki, Japan, leukemia 
incidence among exposed survivors is increased markedly. It might have begun as early as 
one and a half years after the bombing. The increased incidence was demonstrated only 




Certain groups which are associated with genetic abnonnality have greater than 
normal risk for developing acute leukemia The risk for patients with Down Syndrome is 
about 1%. Siblings of children with leukemia have a four-fold higher risk. In identical twins 
if one of the child is diagnosed as having leukemia the chances of developing leukemia in the 
other twin is approximately 20% within six months of the diagnosis. 
1.2.5 Geographic differences 
Although the incidence of leukemia differs significantly between countries but the 
differences is not much and rarely exceed two fold Of the different types of cancer, leukemia 
probably shows the least of geographic variation. 
1.3 Flow Cytometer 
. The flow cytometer (FCM) has been hailed as a new product of technical revolution, 
but the concept ofFCM has existed for over 50 years, and cell counters have been used 
extensively for more than 20 years. Nevertheless, the emergence of the fluorescence detector 
in the new generation of cytometers greatly enhanced their versatility. The availability of a 
great variety of monoclonal antibodies finally pushed FCM to the forefront. 
FCM has the advantage of being more efficient, sensitive., accurate and reproducible 
than manual techniques. With FCM, multiple specimens can be simultaneously processed 
with a panel of 10 or more, and tests can be completed within several hours. When there is 
sufficient specimen, FCM counts 3,000 to 5,000 cells for the study of each antigen compared 
with 100 to 200 cells counted in manual techniques. The major merit ofFCM is its capability 
of measuring multiple parameters forward light scatter, side scatter and fluorescence) 
simultaneously, and the data thus obtained can be stored for further analysis. In addition, the 
electronic gating gadget enables the study of separate cell groups without evoking tedious 
isolation techniques. 
Figure 1.1 : Flowcytometer 
1.3.1 Flow Cytometric immunophenotvping In Acute Leukaemias 
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Flow cytometry is a method to differentiate and count cells and microparticles. It is a 
process in which the measurements are made while the cells or particles pass, preferably in 
single flow through the measuring apparatus in a fluid stream. According to Howard Shapiro: 
"Cytometry refers to the measurement of physical and/or chemical characteristics of cells or, 
by extension, of other biological properties". 
Flow cytometry uses fluorescent lights which the flourochrome absorbs energy from 
laser then releases the absorbed energy by vibration and heat dissipitation. It will than 
showed the relatives sizes of cells, the relative granularity and fluorescence intensity. 
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Components of a flow cytometry are fluidics, optics and electronics. Fluidics to 
introduce and restrict cells for interrogation, optics to generate and collection of lights signals 
and electronics to convert optical signals to an electronic form and also to digitize signals for 
computer analysis. 
Although morphology itself is useful in the classification of acute leukaemias, 
immunophenotyping is better in diagnosing the types of acute leukaemia more accurately. 
Immunophenotyping uses the antigens on the cell surface to react with matching monoclonal 
antibodies (mAbs). Several hundred monoclonal antibodies have been assigned to Clusters of 
Differentiation (CD) groupings by the International Workshops on Leukocyte Differentiation 
Antigens studied by Kishimoto et at. 
Figure 1.2 : Basic of flowcvtometer 
8 
Clinical flow cytometers are designed to measure light scattered by a cell at two 
different and distinct angles, while at the same time measuring one or more fluorescence 
emission signals. All measurements are performed while the cells are injected, single file, 
through a flow cell. In order to arrange cells in such a configuration, the cells are pushed 
through a coaxial liquid stream. The cells are in the core stream, which is surrounded by a 
second stream caJied the sheath stream. The sheath stream is actually a tube or cylinder of 
celJ-ftee fluid surrounding the core stream which contains the cells aligned in single file. This 
phenomenon is called hydrodynamic focusing. The velocities of the two streams are adjusted 
to obtain laminar flow. The sheath flow is adjusted to position the cells in the proper 
observation region in the center of the core stream in a stable flow environment. As the 
stationary laser light intercepts cells one at a time, the positioning of each cell must be 
precise. The inside diameter of capillary in the flow chaJnber was 75-200J.1m. The size of the 
celJs that must pass through the flow system predetermines the diameter of the orifice of the 
flow cell to be used There is a trade-off between a narrow orifice, which provides an ideal 
single-file celJ stream in the flow cell, and a wide orifice, which virtually never clogs. The 
observation region which is also called the interrogation zone is the spot where the moving 
cell intercepts the stationary laser light. The instrument is equipped with beam focusing 
lenses to provide a focused light bundle on cells as they pass the observation point 
The optical system of the flow cytometer is designed to make measurements of 
illuminated cells. Scattered light, an intrinsic parameter, occurs when light is deflected off 
cells, and is detected simultaneously in two different directions. Light is collected at 90° 
(orthogonal light) from the axis of the light beam, and in a forward direction blocker, or 
obscuration bar, is essential to assure that only the forward scattered light is collected and 
that the beam light at 0° is stopped. 
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Fluorescence signal detection on clinical flow cytometers is an extrinsic cellular 
parameter. The distinction between intrinsic and extrinsic cellular parameters will be covered 
in more detail later in this review. In most instruments, the collection of the fluorescence 
signal is shared with the orthogonal light collection system. Various optical mirrors and 
filters are used to reflect and absorb light, respectively. The filtered light signal is deflected 
into a photomultiplier tube {PMT). This device converts light energy into electric current. 
Most clinical instruments operate with a single laser and are capable of detecting two or three 
different flourochromes simultaneously. 
Fluorescent dyes that have been successfully direct-coupled to monoclonal antibodies 
fall into three categories. These are low-molecular-weight organic dyes, bi.ological pigments, 
and the tandem dyes systems (IDS), with energy transfer between two chemically bound 
dyes. There are commercially available dyes from all three of these categories. 
Signal processing and signal acquisition professes to be the least user-friendly 
attributes of clinical flow cytometry. With current instruments, most of the acquisition 
decisions are reduced to algorithms that are preset protocols selected by the operator. The 
on board software is designed to handle this sequence of operations during data acquisition. 
To detect various cell clusters, a wide dynamic range of signal detection is required. 
Heterogeneous populations of cells can be visualized in a single dot plot, and 
morphologically or immunologically different clusters can be resolved. 
Each detection system on a flow cytometer represents a parameter. In order to acquire 
dual light scatter, and one set of fluorescence signals, the minimum of a three-parameter 
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acquisition is required. Five-parameter acquisition is preferred so that both linear scatter data 
is available to the investigor from list mode. In this mode of flow cytometer storage mode, 
data from all the acquired parameters of the cells analyzed are stored on an electronic media. 
On most instruments, fluorescence signals are collected only in logarithmic-scale format. 
Conventional clinical immunophenotyping protocols traditionally trigger on two light scatter 
parameters simultaneously. Initially, cell sorters were designed to trigger on a single-
parameter fluorescence signal. 
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Figure 1.3 : Examples results of flowcytometrv analysis 
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2.0 LITERATURE REVIEW 
2.1 General 
Many studies critically evaluate the diagnostic usefulness of flow cytometric 
immunophenotyping of acute leukemia and provide guidelines for the judicious use of 
immunomarkers and proper interpretation of results (Bruce H. Davis et al, 2000, Gregory T. 
Stelzer e~ al, 1997 and Edward G. Weir et al, 2001 ). 
One of the most relevant and recent studies, is a study done in Kuala Lwnpur 
Hospital from the year 1997-2002 for immunophenotyping of acute leukemia. 
This study used 990 acute leukemia cases which were collected within a period of 5 years. It 
showed that ALL constituted 50% of all cases, AML 48.9% and biphenotypic leukemia is 
1.1% (K mariammah et al, 2003). 
Another study was done in Kelantan State using 45 cases of childhood acute leukemia 
(Menon BS et al, 1998). This study showed that ALL constituted 80% of all childhood cases 
of acute leukemia, while AML only 20%. 
Aside from identification of blasts, flow cytometry was found to be especially useful 
in correct identification of AML Mo, APL (AML-M3) from AML-M1/M2, deoxynucleotidal 
transferase terminal (TdT)-negative ALL unusual variant, such as transitional B-cell ALL 
and hi phenotypic acute leukemia (Zahid Kaleem et al,2003 ). 
Flow cytometry was also found to be useful in the detection of the atypical blasts 
phenotypes existing in 31% of newly diagnosed patients with acute leukaemia with co-
expression of CD 19 and CD2 markers in AML, co-expression of CD33 marker in ALL , co-
expression ofCD19 marker in T cell ALL, and biphenotypic (mixed-lineage) leukaemia 
(Piatoska-Jakubas Bet, al, 1996). 
2.2 Classification of Acute Leukemias 
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The French-American-British (FAB) classification has been used as the basis for the 
classification of acute leukemia for many years. However, the proposed World Health 
Organization (WHO) classification has made many changes on the F AB classification 
(Daniel Catovsky et al, 2002). The F AB classification divides ALL into L~, L2 and L3 but the 
WHO classification considers that the division of Lt and L2 does not serve any clinical 
purposes and merges them into precursor B-cell and precursor T -cell ALLs. L3 is retained as 
Burkitt cell leukemia. In AML, the original F AB categories, Mo, M~, M2, M3, ~, M 5, ~, 
and M7, are now under the tittle of AML not otherwise categorized, which also includes 
acute basophilic leukemia and acute panmyelosis with myelofibrosis (J.A Whittaker et al). In 
addition, there are AML 's with recurrent cytogenetic translocations; AML with multilineage 
dysplasia; and AML with myelodysplastic syndrome, therapy related; and biphenotypic acute 
leukemia The addition of these new entities is due to their clinical relevance. 
2.3 Acute Myeloblastic Leukemia <AML) 
2.3.1 Acute myeloid leukemia without morphologic or cytochemical evidence of 
differentiation <AML Mol:. 
Leukemia that are devoid of detectable MPO should be classified as AML Mo only in 
the absence of lineage-restricted lymphoid and megakaryocytic antigens. Although the cells 
of most Moexpress CD13 or CD33, some cases may lack these antigens. The expression of 
CD 117 by leukemic cells is strongly suggestive of AML (Tsieh Sun, 2002). 
2.3.2 Acute 1'1yelocvtic Leukemia with little differentiation (AML Md 
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AML M1 cases commonly express MPO, CD 13, CD 33, CD 34, CD 65, CD117 and 
HLA-DR but in variable combinations. Expressions ofCD4, CD15 and CD66 are less 
frequent. By using cytochemical, stains o(.Myeloperoxidase (MPO) and chloroacetate 
esterase (CAE) were positive, whereas a-naphtyl butyrate esterase (NBE) and terminal 
deoxynucleotidyl transferase (TdT) were negative in both the bone marrow and peripheral 
blood specimens (Daniel Catovsky et al, 2002). 
The basic requirement for the diagnosis of AML is that more than 30% of all 
nucleated marrow cells are blasts and less than 50% are erythroid precursors except for 
erythroleukemia (Knox-Macaulay HHM et al, 2000). Cytochemical staining can be totally 
negative in AML, and sometimes the staining is difficult to interpret or inconclusive. 
Therefore, immunophenotyping is helpful in substantiating the diagnosis, reliable predictors 
for prognosis (Tsieh Sun, 2002). 
2.3.2.1 Features for Laboratory Diagnosis of AML-Mi (Tsieh Sun, 2002). 
,/ Greater than 90% myeloblasts in the bone marrow or peripheral blood 
v' Greater than 3% MPO-positive blasts in the bone marrow 
v' Blasts positive for CAE but negative for NBE 
v' Blasts positive for CD33/CD 13, HLA-DR 
v' Blasts negative for CD14, CD15, CD41/CD61, Glycophorin A 
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2.3.3 Acute Myeloblastic Leukemia witb Maturation (Ml) 
Leukemic blast cells commonly express MPO, CD34, CD65 and ~A-DR but CDI3 
and CD33 expression is chamcteristically very weak Myeloperoxidase (MPO) and 
chloroacetate esterase (CAE) were positive, and a-naphtyl butyrate esterase (NBE) was 
negative for blasts in the bone marrow. 
The major diagnostic criterion for A1vfL-M2 is based on the blast count in the bone 
marrow. Peripheml blood showed many blasts containing multiple Auer rods. This subtype is 
usually associated with favorable prognosis (Edward G. Weir et al, 2001 ). 
2.3.3.1 .Features for Laboratory diagnosis of Acute Myelogenous Leukemia-M2 : 
./ 20-90% ofmyeloblasts present in bone marrow 
./ Less than 20% monocytic precursors in the bone marrow 
./ Less than 5 x I 09 /L monocytic components in the peripheral blood 
./ Cytochemical stain for blasts 
• Positive for myeloperoxidase and choloroacetate esterase 
• Negative for a-naphthyl butyrate 
./ Monoclonal antibody panel : 
• Positive for CD13, CD15, CD33,HLA-DR 
• Negative for CD 14 
2.3.4 Acute Promyelocytic Leukemia CM~} 
Strongly express MPO, CD13, CD33 and CD65 but usually do not express CD34 or 
HLA-DR. CD 4 and CD 56 are seldom detected (Daniel Catovsky et al, 2002). Leukemic 
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cells from both the peripheral blood and bone marrow were positive for myeloperoxidase 
(MPO) and choloroacetate esterase (CAE) stains but negative for a-naphtyl butyrate esterase 
(NBE) stain. CAE stain also demonstrated single or multiple Auer rods in leukemic cells. 
AML-M3 was originally designated hypergranular promyelocytic leukemia by the F AB 
group (Edward G. Weir et al, 2001). 
2.3.4.1 Features for Laboratory Diagnosis of AML-M~(Tsieh Sun, 2002) . 
./ Presence of more than 20% hypergranular (or microgranular) promyelocytes in the 
bone marrow 
./ Presence of multiple Auer rods in the cytoplasm of leukemic cells 
./ Cytochemical staining: Strongly positive for myeloperoxidase and choloroacetate 
esterase, but negative for a-naphtyl butyrate esterase . 
./ Immunophenotyping: 
Positive: for myelomonocytic antigens (CD13, CD15, CD33) but negative for 
monocytic antigen (CD14) and HLA-DR. 
2.3.5 Acute Myelomonocvtic Leukemia ~} 
Blast cells of most myelomonocytic leukemia express MPO, CD4, CD13, CD14, 
CD33, CD 34, CD45, CD65 andHLA-DR. In adults, CD19 also frequently expressed 
(Daniel Catovsky eta/, 2002). In the bone marrow and peripheral blood specimens, the 
myeloperoxidase (MPO), chloroacetate esterase (CAE), and a-naphtyl butyrate esterase 
(NBE) stains were all positive for leukemic cells. 
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AML-~ accounts for 20% of AML cases. The diagnostic criterion as defined by the 
F AB group is the presence of 30% of blasts in the bone marrow, including type I and type II 
myeloblasts, monoblasts and promonocytes (J.A Whittaker et al, 1987). 
2.3.5.1 Features for Laboratory Diagnosis of AML-M. (Tsieh Sun, 2002). 
-/ Presence of at least 20% myeloblasts-monoblasts-promonocytes in bone marrow 
../ Both myeloblasts and monoblasts/promoncytes should exceed 20% 
../ If monocytic component is less than 20% in bone marrow: 
• Monocyte count in peripheral blood should be greater than 5 x 109/L 
• Serum lysozyme level should exceed three times the normal value 
./ Myeloperoxidase positive cells must be more than 3% 
./ Chloroacetate esterase and a-naphtyl butyrate esterase-positive cells were roughly 
more than 20% each 
./ bmrr.nunopheno~ 
• Positive: CD13, CD14, CD33 and HLA-DR 
• Negative: CD41/CD42/CD61 and Glycophorin A 
2.3.6 Acute Mono blastic Leukemia ~) 
Expression of CD 14 is largely restricted to cells of the monocytic lineage but is often 
absent in pediatric Ms cases. In both bone marrow and peripheral blood specimens, more 
than 3% of blasts showed myeloperoxidase (MPO) staining, and more than 80% of blasts in 
the bone marrow were monoblasts that were positive for a-naphtyl butyrate esterase. None of 
the immature cells were stained with chloroacetate esterase (CAE). The terminal 
deoxynucleotidyl transferase was negative in both specimens (J.A Whittaker et al, 1987). 
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The F AB criteria for the diagnosis of AML-M5 require 80% or more of the 
nonerythroid cells in the bone marrow to be monoblasts, promonocytes, or monocytes. If the 
predominant component (>80%) is monoblasts, the condition is designated M5a, whereas the 
predominant components should be promonocytes and monocytes in M 5b (Daniel Catovsky 
et al, 2002 ). 
The immunophenotype is slightly different between M5a and M5b. CD 14 expression 
is more consistent in Msb cases, whereas in Msa about one-third of cases show absence or 
low percentage of CD 14 positivity. Another study has showed that CD 117 is frequently 
positive in M5a and negative in Msb cases, whereas CD4 is often positive in M5b but 
·... negative in M5a (Edward G. Weir et al, 2001). 
2.3.6.1 Features for Laboratory Diagnosis of M~(Tsieh Sun, 2002). 
-/ Presence of more than 80% monocytic component among the nonerythroid cells in 
the bone marrow 
• M5a: 80% or more of moncytic components are monoblasts 
• M5b: Predominantly monocytes and promonocytes 
./ Elevation of serum and urine lysozyme levels 
./ Cytochemistry 
• Myeloperoxidase: may or may not be positive 
• Nonspecific esterase: Strongly positive 
• Specific esterase and periodic acid-Schiff: Usually negative 
18 
./ Immunophetype: 
• Positive for CD13, CD14, CD33 and HLA-DR 
• Negative for CD41, CD61 and glycophorin A. 
2.3. 7 Acute Erythroleukemia (M6} 
Leukemic erythroblasts usually express CD36, CD71 and Glycophorin A. Cells of 
myeloid component express CD13, CD33, and l\1PO. The leukemic cells (mainly the 
myeloblasts) showed positive staining for myeloperoxidase and chloroacetate esterase but 
negative staining for a-naphtyl butyrate esterase. The erythroblasts showed the typical block 
pattern in the PAS stained preparation. An immunoflourescence stain for tenninal 
deoxynucleotidyl transferase was negative (Daniel Catovsky et al, 2002). 
Erythroleukemia~ is a rare disease, accounting for 4% to 5% of AML. The F AB 
criteria for~ is the presence of at least 50% normoblasts ( erythroblasts) among the total 
number of nucleated cells and 30% type I and type IT blasts among the nonerythroid 
population in the bone marrow. Kowal-Vern et al. suggested that cases with pronormoblasts 
more than 30% should be considered erythroleukemia rather than myelodysplastic syndrome, 
because their clinical behavior is more consistent with leukemia than dysplasia. 
M6 cases are pleomorphic and sometimes unclassifiable morphologically. 
Immunologic identification oferythroblasts becomes necessary. Several antibodies can help 
identify the erythdoid series. Gupta and Dhond et al. used a panel of monoclonal antibodies 
specific for different developmental stages (erythrocyte burst-forming units, erythrocyte 
colony-forming units, nonnoblasts, and erythrocytes) and components (glycophorin A and H 
antigens) of erythroid cells and found that in most cases ofM6, the phenotype of the 
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prononnoblasts was that of the intermediate stage of maturation. Transferin receptor antibody 
(CD71) has also been used to detect mature and immature nucleated erythrocytes. 
2.3.7.1Features for Laboratory Diagnosis of I\£; (Tsieh Sun, 2002) . 
../ ~a: Presence of more than 50% of normoblasts among all nucleated cells and 20% 
of myeloblasts among nonerythroid cells in the bone marrow . 
./ ~b: Presence of more than 80% of pronormoblasts and basophilic normoblasts but 
less than 20% of myeloblasts in the bone marrow . 
./ PAS positive in mature and immature nucleated erythroid cells . 
../ Glycophorin-A or other erythroid antibodies: The only reliable antibodies for 
immunophenotyping . 
../ React variably to myelomonocytic (CD13, CD33) and platelet (CD41) antibodies. 
2.3.8 Acute Megakarvoblastic Leukemia (M,} 
The leukemic cells of most AML M1 cases express CD41a and CD61. Most cases are 
positive for CD4 and CD 33. CD13, CD34, CD36, CD45, and HLA-DR are infrequently 
detected (Tsieh Sun, 2002). 
The leukemic cells in the bone marrow were negative for myeloperoxidase and a-
naphtyl butyrate esterase but positive for choloroacetate esterase and PAS stains. The PAS 
stain showed a typical peripheral pattern with strong staining in the cytoplasmic blebs. An 
immunoflourescence stain for the terminal deoxynucleotidyl transferase was negative 
(Edward G. Weir et al, 2001). 
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The F AB criterion for the diagnosis of M1 is the presence of 30% or more 
megakaryoblasts in the bone marrow. It requires the identification of megakaryocytic cells 
not only by morphology but also by either the platelet peroxidase reaction on electron 
microscopy or tests with monoclonal or polyclonal platelet specific antibodies (J.A Whittaker 
et al, 1987). 
The monoclonal antibodies most commonly used are CD41, CD61 and CD42. For 
myelomonocytic antigens, CD33 is frequently positive, but CD 13 and CD 14 are usually 
negative. CD 34, a hemopoeitic progenitor cell antigen and CD56, a neural cell adhesion 
molecule and natural killer marker, are frequently expressed on megakaryoblasts. The 
expression ofHLA-DR is variable. However, recent study showed that CD2 and CD7 were 
relatively common in M1 {Tiensiwakul P et al, 1999). The PAS stain demonstrated the 
characteristic peripheral pattern, which may represent the maturing platelets on the surface of 
the megakaryocytes or megakaryoblasts. 
2.3.8.1 Features for Laboratory Diagnosis of M, {Tsieh Sun, 2002) . 
./ Presence of 20% or more megakaryoblasts in the bone marrow . 
./ Excess of blasts with increased numbers of maturing megakaryocytes in the bone 
marrow biopsy, plus identification of megakaryoblasts in the peripheral blood and 
bone marrow aspirate by immunologic techniques 
./ Electron microscopic identification of platelet peroxidase in leukemic cells . 
./ Monoclonal antibodies: CD41, CD42, and CD61 are specific for megakaryoblasts 
./ Myelomonocytic markers: Positive for CD33 but negative for CD13 and CD14. 
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./ PAS staining pattern in megakaryocyte-megakaryoblasts with periphery of cytoplasm 
with accentuation on cytoplasmic blebs. 
2.4 Acute Lymphoblastic Leukemia (ALL) 
2.4.1 Acute Lymphoblastic Leukemia of B-Celi Lineage 
Terminal deoxynucleotidyl transferase (TdT) was positive in 100% of blasts in both 
the bone marrow and the peripheral blood specimens. Myeloperoxidase was negative. ALL is 
leukemia with proliferation of lymphoblasts involving both the bone marrow and the 
peripheral blood. Lymphoblasts may not be demonstrated in the peripheral blood in 
occasional ALL cases (a leukemic leukemia). About one third of patients have a total white 
cell count of less than 5 x 109 I L {Tsieh Sun, 2002). 
There are some subgroups that consists ofB-precursor ALL, pre-BALL and B-ALL. 
These stages can be distinguished by using CD19, Cp and surface immunoglobulin. B-
precursor ALL shows only CD19, pre-BALL expresses CD19 and Cp, whereas B-ALL 
bears CD 19 and surface immunoglobulin. The malignant nature of the ALL cells is 
determined by TdT, CD 10 (common ALL antigen), andCD34 (hematopoeitic progenitor 
antigen) (Gerald E. Marti et al, 2001). TdT is present in most cases of ALL except forB-
ALL. CD 10 is seen in most cases ofB-cell ALL. CD34 is present in B-precursor ALL but 
not in pre-B ALL and some cases of B-ALL. Additional antibodies that can be helpful in 
classifying ALL include HLA-DR, CD20, CD22, and CD24. Cytoplasmic CD22 appears 
earlier in the B-cell developmental stage than surface CD22 and consistently positive in B-
ALL 
2.4.1.1 Features for Laboratory diagnosis of B-ceU ALL (Tsieh Sun, 2002) . 
./ TdT positive for precursor-S and pre-B ALL 
./ CDlO positive, except for some B-ALL cases 
./ HLA-DR positive 
./ CD19 frequently present without CD20 
./ CJ.l positive in pre-B ALL only 
./ Monoclonal surface immunoglobulin in B-ALL only 
2.4.2 Acute Lymphoblastic Leukemia ofT -Cell Lineage 
22 
T -cell ALL may show either L1 or L2 morphology, whereas LJ is always of B-cell 
lineage. The cytochemical reactions in T -cell ALL are the same as B-cell ALL. When a high 
percentage of tumor cells stains for TdT, the diagnosis of ALL is certain. Although a small 
percentage of acute myeloblastic leukemia (AML) cases may show positive TdT, the 
percentage of positive leukemic cells is usually much lower. In other words, only a small 
subset of leukemic cells may express TdT in AML cases. PAS positivity helps establish the 
diagnosis, but a negative PAS reaction does not rule out ALL (Tsieh Sun, 2002). 
The most comprehensive immunologic classification divides T -cell ALL into four 
immunophenotypes which are the pre-T, early cortical, late cortical and medullary. The pre-
Tcell phenotype expresses only CD7, cytoplasmic CD3, and TdT without other T -cell 
antigens. The early cortical phenotype shows CD2, CDS, CD7 and strong TdT. The late 
cortical phenotype reveals CD 1, CD2, CDS, CD7 and dual CD4/CD8 with minimal surface 
CD3 (Gerald E. Marti et al, 2001 ). The medullary phenotype shows CD2, CD3, CDS, CD7 
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and segregated CD4 or CDS. TdT is not commonly expressed in this phenotype. Cytoplasmic 
CD3 expressed in all stages. 
2.4.2.1 Features For Laboratory Diagnosis ofT -ceO ALL (Tsieh Sun, 2002) . 
./ Most cases are positive for TdT 
./ Pediatric cases are frequently negative for COlO andHLA-DR 
./ CD7 is frequently the only positive T -Cell marker, but all T -cell markers can be 
present. 
./ Dual CD4/CD8 positivity is most common than other CD4/CD8 combinations. 
Table 1.1 : Morphologic lFABl classification of ALL (Daniel Catovsky et al, 2002) 
Lt ~ 4 
Size of blasts Small, uniform Large, variable Medium to large, 
uniform 
Amount of Scanty variable Moderate 
cyto____masm 
Cytoplasmic Moderate variable Intense 
basophilia 
Cytoplasmic Variable variable Prominent 
vacuoles 
Nucleus Regular, occasional Irregular, clefting Regular, nonclefted, 
clefting, common, homogeneous, 
homogenous heterogeneous finely stippled 
chromatin chromatin chromatin 
Nucleolus 0-l,Unconspicuous 1 or more, 2-5, prominent 
prominent 
Nuclear/cytoplasmic High Low Low 
ratio 
2.5 Supplementary Tests 
With the proliferation of new monoclonal antibodies and the improvement of 
instruments, FCM bas become increasingly useful. However, flow cytometer is still not an 
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entirely independent tool for the diagnosis of hematologic neoplasms. These are some 





• Southern Blotting 
• Quantitative Polymerase Chain Reaction 
• Cytogenetics 
• Flourescence in situ Hybridization (FISH) 
• Oncogenes 
Cytochemistry is an integral part in the diagnosis of AML required by the French-
American-British Cooperative Group. Myeloperoxidase (MPO) stain is the first screening 
test to distinguish AML from ALL. This enzyme is present in neutrophilic, eosinophilic, and 
monocytic lineage but not in lymphocytes. The MPO in eosinophils is resistant to cyanide, so 
that eosinophil and its immature fonns can be identified this specific reaction. The 
peroxidase of megakaryocytes and platelets cannot be visualized by light microscopy, but it 
can be demonstrated by electron microscopy (Tsieh Sun, 2002). 
Acid phophatases (APs) are a group of enzymes capable of hydrolyzing 
monophosphates esters in an acid environment By electrophoresis, APs can be separated as 
seven nonerythrocytic isoenzymes. Isoenzymes 2 and 4 are present in neutrophils and 
